- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04115319
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia.
This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Brasov, Romania, 500079
- Spitalul de Psihiatrie si Neurologie Brasov, Sectia Psihiatrie Clinica III, Str. Mihai Eminescu,
-
Brasov, Romania, 500079
- Spitalul Universitar de Urgenta Militar Central "Dr. Carol Davila", Sectia Psihiatrie
-
Bucuresti, Romania, 041914
- Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia", Sectia Psihiatrie XII
-
Bucuresti, Romania, 060222
- Centrul de Evaluare si Tratament al Toxicodependentelor pentru Tineri "Sfantul Stelian",
-
Bucuresti, Romania, 41914,
- Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia, Sectia Clinica Psihiatrie XIII
-
Iasi, Romania, 700282
- Institutul de Psihiatrie Socola Iasi
-
-
-
-
-
Arkhangelsk, Russian Federation, 163530
- State Budgetary Institution of Healthcare "Arkhangelsk Regional Clinical Psychiatric Hospital"
-
Ekaterinburg, Russian Federation, 620030
- State Budgetary Institution of Heathcare of Sverdlovsk Region "Sverdlovsk Regional Clinical Psychiatric Hospital"
-
Leningrad, Russian Federation, 188357
- Saint Petersburg State Budgetary Institution of Healthcare "Psychiatric Hospital named after P.P. Kashchenko"
-
Moscow, Russian Federation, 127083
- State Budgetary Healthcare Institution of Moscow Region "Central Clinical Psychiatric Hospital"
-
Omsk, Russian Federation, 644070
- Budgetary Institution of Healthcare of Omsk region "Clinical Psychiatric Hospital n.a. N.N. Solodovnikov"
-
Saint Petersburg, Russian Federation, 190121
- Saint Petersburg State Public Institution of Healthcare "Psychiatric Hospital of Saint Nikolai Chudotvorets"
-
Saint Petersburg, Russian Federation, 192019
- Federal State Budgetary Institution "National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev" MoH RF
-
Saint Petersburg, Russian Federation, 192019
- Federal State Budgetary Institution "National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev"
-
Saint Petersburg, Russian Federation, 195176
- Saint Petersburg State Budgetary Institution of Healthcare "City Psychoneurological Dispensary #5"
-
Saint Petersburg, Russian Federation, 199106
- Saint Petersburg State Budgetary Institution of Healthcare "Psychoneurological Dispensay No 1"
-
Smolensk, Russian Federation, 214031
- FSBEI HE "Smolensk State Medical University" of the MoH of the RF leg add: 28, Krupskoi str, Smolensk, Smolensk region, 214019; act add: 46-a, Kirova str, Smolensk
-
St-Petersburg, Russian Federation, 190121
- S St-Petersburg state budget institution Psychoneurological dispensary #10
-
Stavropol, Russian Federation, 357034
- State Budgetary Institution of Healthcare of Stavropol territory "Regional Specialization Psychiatry Hospital # 2"
-
Tomsk, Russian Federation, 634014
- LLC "Clinic Stolet" 30, Derbyshevskiy lane, Tomsk, Tomsk region, 634009, Russia based on FSBSI "Tomsk National Research Medical Center of Russian Academy of Sciences"
-
Yaroslavl, Russian Federation, 150003
- State Budgetary Institution of Healthcare of Yaroslavl region "Yaroslavl Regional Clinical Psychiatric Hospital"
-
-
-
-
-
Ivano-Frankivsk, Ukraine, 76011
- Communal Non-commercial Enterprise Carpathian Regional Clinical Center of Mental Health of Ivano-Frankivsk Regional Council, Department of Neuroses and Edge Conditions/States #8
-
Kharkiv, Ukraine, 61068
- State Institution Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Unit of Clinical, Social and Child Psychiatry
-
Kharkiv, Ukraine, 61068
- State Institution Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Unit of Emergency Psychiatry and Narcology
-
Kyiv, Ukraine, 03049
- Kyiv Clinical Hospital on Railway Transport #2 of Healthcare Center branch of JSC "Ukrainian Railway", Consultative and Diagnostic Center of Policlinic
-
Smila, Ukraine, 20708
- Communal Noncommercial Enterprise Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council, Female Department #11, Male Department #12
-
Ternopil, Ukraine, 46027
- Communal Non-commercial Enterprise Ternopil Regional Clinical Psychoneurological Hospital of Ternopil Regional Council, Department of Psychiatry #2 (male), Department of Psychiatry #6 (female), Ternopil I.Ya. Gorbachevskyi National Medical University of t
-
Uzhgorod, Ukraine, 88000
- Communal Noncommercial Enterprise Transcarpathian Regional Medical Center of Mental Health and Medicine of Addictions of Transcarpathian Regional Council, Department of Psychiatry
-
-
-
-
California
-
Cerritos, California, United States, 90703
- Synexus Clinical Research US, Inc.
-
Oakland, California, United States, 94607
- Pacific Research Partners
-
Oceanside, California, United States, 92056
- Excell Research
-
San Diego, California, United States, 92103
- Artemis Institute for Clinical Research
-
Torrance, California, United States, 90502
- Collaborative Neuroscience Network
-
-
Florida
-
Miami, Florida, United States, 33122
- Premier Clinical Research Institute
-
Miami Lakes, Florida, United States, 33016
- Innovative Clinical Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Synexus Clinical Research US
-
-
Illinois
-
Hoffman Estates, Illinois, United States, 60169
- Alexian Brothers Center for Psychiatric Research
-
Lincolnwood, Illinois, United States, 60712
- Pillar Clinical Research
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Louisiana Clinical Research
-
-
Missouri
-
Saint Louis, Missouri, United States, 63128
- PsychCare Consultants Research
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- Dean-Yurie, Altea Research
-
-
New York
-
Cedarhurst, New York, United States, 11516
- Krzsztof Wroblewi-Neurobehavioral Research Inc.
-
Jamaica, New York, United States, 11432
- Tyne Moeller-Synexus Clinical Research US Inc.
-
Rochester, New York, United States, 14618
- Finger Lakes Clinical Research
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28211
- New Hope Clinical Research
-
-
Ohio
-
North Canton, Ohio, United States, 44720
- Dr. Shishuka Malhorta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
The main inclusion criteria include, but are not limited to the following:
- Male or female subject between 18 to 65 years of age (inclusive) at the time of consent.
- Subject meets DSM-5 criteria for a diagnosis of schizophrenia as established by clinical interview at screening (using the DSM-5 as a reference and confirmed using the SCID-CT). The time since the subject's diagnosis must be ≥ 1 year prior to Screening.
- Subject must have a CGI-S score ≤ 4 at Screening and Baseline.
- Subject must have a PANSS total score ≤ 80 at Screening and Baseline.
- Subject is judged to be clinically stable (i.e., no evidence of an acute exacerbation) by the Investigator for at least 8 weeks prior to Screening.
- Subject has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes are permitted) for at least 6 weeks prior to Screening.
- Subjects taking an antipsychotic agent at Screening may participate in this study only if there are signs of intolerability or lack of efficacy of the current antipsychotic (as determined by the Investigator).
- Subject is, in the opinion of the Investigator, generally healthy based on Screening medical history, PE, neurological examination, vital signs, electrocardiogram (ECG) and clinical laboratory values (hematology, chemistry and urinalysis).
Exclusion criteria:
Main exclusion criteria include, but are not limited to:
- Subject was hospitalized for a psychiatric illness within the 8 weeks prior to Screening.
- Subject has a current DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, schizoaffective disorder, ,bipolar I or II disorder, obsessive compulsive disorder, and posttraumatic stress disorder, symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as theses symptoms are not the primary focus of treatment.
- Subject is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents within a 1-year period prior to Screening, given at adequate dose as per labeling, for at least 4 weeks.
- Subject answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Screening (i.e., in the past one month) or at Baseline (i.e., since last visit).
- Subject is at significant risk of harming self or others based on Investigator's judgment.
- Subject has attempted suicide within 6 months prior to Screening.
- Subject has received treatment with a psychotropic medication or herbal supplement within 3 days or 5 half-lives (whichever is longer)
- Subject has been treated with quetiapine or quetiapine XR within the 6 weeks prior to Screening or has a history of inadequate response or intolerability to quetiapine or quetiapine XR.
- Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
- Subject has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SEP363856
SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
|
SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
|
Active Comparator: quetiapine XR
quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
|
quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation
Time Frame: 52 Weeks
|
52 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: CNS Medical Director, Sumitomo Pharma America, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SEP361-304
- 2019-002259-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on SEP363856
-
SunovionCompleted
-
SunovionCompleted